Abstract
Coronavirus Disease-19 (COVID-19), caused by SARS-CoV-2 infection, is associated with a rise in inflammatory markers which can result in altered coagulation system activation and regulation. During COVID-19, a remarkable tendency towards venous thrombosis and thrombo-embolism has been widely reported, especially in the critically ill patients. Thus, to limit this clinically relevant events, various strategies of venous thrombo-prophylaxis and anticoagulation have been studied. On the other hand, arterial thrombosis seems to play a less relevant role the clinical picture of COVID-19, as much as bleeding complications, which are mostly correlated to anticoagulation management. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.